SBX.XETRA SynBiotic SE
- Market cap
- EUR 1.02M
- P/E
- -
- P/B
- 0.17x
- ROE
- -42.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is SBX.XETRA undervalued?
Graham numberThe Graham number of SynBiotic SE cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SynBiotic SE fundamental analysis
No fundamental analysis for SynBiotic SE yet.
SynBiotic SE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SynBiotic SE
SynBiotic SE, together with its subsidiaries, engages in the pharmaceutical business in Germany and Europe. It is involved in the cultivation, research, development, production, and distribution of medicinal cannabis; industrial hemp; and cannabidiol and cannabinoid-based products. The company was incorporated in 2024 and is based in Düsseldorf, Germany.
Full company profileSynBiotic SE financial statements
SynBiotic SE annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 5.45M | 8.65M | 8.17M | 3.86M | 14.3M |
| Gross Profit | - | - | 3.71M | 4.79M | 3.57M | 1.51M | 4.86M |
| Operating Income | -822.00 | -13.4K | -721K | -11.4M | -24.9M | -11.0M | -10.5M |
| EBITDA | -822.00 | -13.4K | -716K | -12.6M | -24.4M | -7.12M | -2.03M |
| Net Income | -822.00 | -13.4K | -880K | -12.7M | -24.4M | -10.6M | -9.72M |
| EPS | 0.00 | -0.05 | -0.55 | -4.10 | -5.90 | -2.24 | -1.66 |
| Balance Sheet | |||||||
| Total Assets | 250K | 238K | 35.0M | 60.6M | 40.6M | 34.9M | 45.7M |
| Total Liabilities | - | 2.50K | 9.53M | 23.9M | 17.8M | 19.6M | 24.7M |
| Shareholders' Equity | 249K | 236K | 25.5M | 35.0M | 22.6M | 15.8M | 22.9M |
| Cash & Short-term Investments | - | 13.2K | 6.04M | 5.24M | 3.03M | 89.2K | 543K |
| Total Debt | - | - | 367K | 3.43M | 4.45M | 3.68M | 5.51M |
| Cash Flow | |||||||
| Operating Cash Flow | -11.4K | -11.4K | -1.26M | -5.14M | -7.00M | -2.92M | -503K |
| Capital Expenditure | 17.8K | 17.8K | 2.14M | 366K | 478K | 19.2K | 223K |
| Free Cash Flow | - | -11.43 | -3.40M | -5.51M | -7.47M | -2.94M | -726K |
| Ratios | |||||||
| ROE | -0.3% | -5.7% | -3.5% | -36.4% | -107.8% | -67.3% | -42.5% |
| ROA | -0.3% | -5.6% | -2.5% | -21.0% | -60.0% | -30.4% | -21.3% |
| Net Profit Margin | - | - | -16.2% | -147.1% | -298.4% | -275.3% | -67.9% |
| Debt to Equity | - | - | 0.01x | 0.10x | 0.20x | 0.23x | 0.24x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SynBiotic SE dividends
SynBiotic SE has not paid dividends in the last 7 fiscal years.
Who owns SynBiotic SE
Ownership data of SynBiotic SE is not available yet.
SynBiotic SE company profile
- Company name
- SynBiotic SE
- Ticker
- SBX.XETRA
- ISIN
- DE000A3E5A59
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 79
- Fiscal year end
- December
- Address
- Münsterstraße 336, Düsseldorf, Germany, 40470
- Phone
- 49 89 6003 7544
- Website
- synbiotic.com
About SynBiotic SE
SynBiotic SE, together with its subsidiaries, engages in the pharmaceutical business in Germany and Europe. It is involved in the cultivation, research, development, production, and distribution of medicinal cannabis; industrial hemp; and cannabidiol and cannabinoid-based products. The company was incorporated in 2024 and is based in Düsseldorf, Germany.
SynBiotic SE management
2- Mr. Daniel KruseMD & Director
- Ms. Rebecca Kruse-Rosetti?Head of Finance